CHPA “Neutral” On Requiring Deadlines For TEA Reviews
This article was originally published in The Rose Sheet
Executive Summary
CHPA comments on the Senate HELP Committee’s draft legislation that would require FDA to establish review deadlines for TEAs. The trade group says it is “neutral” about the proposal, but offers to help the committee with “more comprehensive reviews of OTC approvals.”
You may also be interested in...
All OTC Ingredient TEAs Get Review Deadlines In Senate Draft Bill
Senate HELP committee leaders release a draft bill for discussion that builds on the Sunscreen Innovation Act and its proposed deadlines for FDA review of sunscreen TEA applications, adding provisions that would require FDA to set “reasonable” review deadlines for all OTC ingredient TEAs.
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.